Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE study of apalutamide with metastasis-directed radiotherapy for oligometastatic prostate cancer
jRCTs031220430Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ADT-free PSA progression-free survival. Started Feb 2023; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs031220430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220430.